Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.50 is 53% above its 5-year average of -1.06, near the high end of its 5-year range (-1.71–-0.30).
33.33% above its 12-month average of -0.75.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.50
EARNINGS PER SHARE (EPS) AVG TTM
-0.75
EARNINGS PER SHARE (EPS) AVG 3Y
-1.17
EARNINGS PER SHARE (EPS) AVG 5Y
-1.06
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+33.33%
CURRENT VS 3Y AVG
+57.36%
CURRENT VS 5Y AVG
+52.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Gain Therapeutics, Inc.
Market Cap
$72.73M
Earnings Per Share (EPS)
-0.50
TTM Avg
-0.75
3Y Avg
-1.17
5Y Avg
-1.06
Market Cap
$71.89M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.44
3Y Avg
-0.60
5Y Avg
-0.58
Market Cap
$69.26M
Earnings Per Share (EPS)
-0.08
TTM Avg
0.13
3Y Avg
-0.17
5Y Avg
-0.10
Market Cap
$68.49M
Earnings Per Share (EPS)
-0.33
TTM Avg
-1.03
3Y Avg
-28.69
5Y Avg
-510.63
Market Cap
$77.54M
Earnings Per Share (EPS)
-2.22
TTM Avg
-3.23
3Y Avg
-3.23
5Y Avg
-3.23
Market Cap
$76.72M
Earnings Per Share (EPS)
-0.38
TTM Avg
-0.49
3Y Avg
-0.66
5Y Avg
-0.75
Market Cap
$67.60M
Earnings Per Share (EPS)
2.68
TTM Avg
-1.38
3Y Avg
-6.44
5Y Avg
-7.90
Market Cap
$78.77M
Earnings Per Share (EPS)
-1.17
TTM Avg
-2.88
3Y Avg
-6.48
5Y Avg
-4.74
Market Cap
$79.62M
Earnings Per Share (EPS)
-1.15
TTM Avg
-1.39
3Y Avg
-1.49
5Y Avg
-1.37
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $72.73M | -0.50 | -0.75 | -1.17 | -1.06 |
| MindWalk Holdings Corp. (HYFT)vs › | $71.89M | -0.26 | -0.44 | -0.60 | -0.58 |
| Champions Oncology, Inc. (CSBR)vs › | $69.26M | -0.08 | 0.13 | -0.17 | -0.10 |
| iBio, Inc. (IBIO)vs › | $68.49M | -0.33 | -1.03 | -28.69 | -510.63 |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | -2.22 | -3.23 | -3.23 | -3.23 |
| Hyperfine, Inc. (HYPR)vs › | $76.72M | -0.38 | -0.49 | -0.66 | -0.75 |
| Fortress Biotech, Inc. (FBIO)vs › | $67.60M | 2.68 | -1.38 | -6.44 | -7.90 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.77M | -1.17 | -2.88 | -6.48 | -4.74 |
| Pulmonx Corporation (LUNG)vs › | $79.62M | -1.15 | -1.39 | -1.49 | -1.37 |
| Cingulate Inc. (CING)vs › | $66.27M | -5.01 | -7.16 | -89.38 | -71.00 |
Trailing EPS (TTM)
$-0.50
Forward EPS (Est.)
$-0.50
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.61 |
| 2024-12-31 | -0.89 |
| 2023-12-31 | -1.71 |
| 2022-12-31 | -1.48 |
| 2021-12-31 | -1.37 |
| 2020-12-31 | -0.30 |
| 2019-12-31 | -0.37 |
| 2018-12-31 | -0.19 |
